Evidence map›Paper›PMID 35794525›Full record

ArticleBMC cancer2022

Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.

Lu-Shan Xiao, Rui-Ning Li, Hao Cui, Chang Hong, Chao-Yi Huang, Qi-Mei Li, Cheng-Yi Hu, Zhong-Yi Dong, Hong-Bo Zhu, Li Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. The Influence of Muscle Morphology on Oncological Outcomes: A Review.Journal of frailty, sarcopenia and falls · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lu-Shan Xiao *Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Rui-Ning Li *Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Hao Cui *Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chang HongDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chao-Yi HuangDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Qi-Mei LiDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Cheng-Yi HuDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zhong-Yi DongDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Hong-Bo ZhuDepartment of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Li LiuBig Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. liuli@i.smu.edu.cn.
Southern Medical University · CNNanfang Hospital · CNUniversity of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have been used to successfully treat primary liver cancer (PLC); however, identifying modifiable patient factors associated with therapeutic benefits is challenging. Obesity is known to be associated with increased survival after ICI treatment; however, the relationship between body composition (muscle, fat) and outcomes is unclear. This study aimed to evaluate the association between sarcopenia and CT-derived fat content and the prognosis of ICIs for the treatment of PLC.

methodsIn this retrospective cohort study of 172 patients with PLC, we measured the skeletal muscle index (SMI), skeletal muscle density, visceral adipose tissue index, subcutaneous adipose tissue index, total adipose tissue index (TATI), and visceral-to-subcutaneous adipose tissue area ratio using CT. In addition, we analyzed the impact of body composition on the prognosis of the patients. Multivariate Cox regression analysis was used to screen for influencing factors.

resultsAmong the seven body composition components, low SMI (sarcopenia) and low TATI were significantly associated with poor clinical outcomes. Multivariate analysis revealed that sarcopenia (hazard ratio [HR], 5.39; 95% confidence interval [CI], 1.74-16.74; p = 0.004) was a significant predictor of overall survival (OS). Kaplan-Meier curves showed that sarcopenia and TATI were significant predictors of OS. Body mass index was not associated with survival outcomes.

conclusionsSarcopenia and fat tissue content appear to be independently associated with reduced survival rates in patients with PLC treated with ICIs.

Indexed as

Liver NeoplasmsSarcopeniaBody CompositionHumansImmune Checkpoint InhibitorsPrognosisRetrospective StudiesTomography, X-Ray ComputedImmune Checkpoint InhibitorsFat tissueImmune checkpoint inhibitorsPrimary liver cancerPrognosisSarcopenia

Identifiers

PMID35794525
PMCPMC9258103
OpenAlexW4283835859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.